The Impact of COVID-19 Pandemic on Cancer Patients
Published: 2022-10-12
Page: 126-130
Issue: 2022 - Volume 5 [Issue 2]
Ming C. Liau *
CDA Therapeutics, Inc. 3308 Sky Run Court, Missouri City, TX 77459, USA.
Linda L. Baker
CDA Therapeutics, Inc. 3308 Sky Run Court, Missouri City, TX 77459, USA.
*Author to whom correspondence should be addressed.
Abstract
The objectives of this study were to bring up chemo-surveillance as an important issue to dictate the display of a fatal symptom of pulmonary fibrosis following infection of COVID-19 that can gravely affect cancer patients and to develop CDA formulations for the therapy of pulmonary fibrosis and cancer. COVID-19 infection triggers biological and immunological responses similar to wound, resulting in the production of prostaglandins to cause symptoms of respiratory illness such as fever and cough, and tumor necrosis factor to cause cachexia symptoms leading to the collapse of chemo-surveillance which is a natural defense mechanism to ensure perfection of wound healing. The collapse of chemo-surveillance promotes the development of pulmonary fibrosis and cancer. The functionality of chemo-surveillance of cancer patients has been badly compromised. Therefore, cancer patients are particularly vulnerable to develop severe symptom of pulmonary fibrosis. Cancer therapies based on cell- killing such as chemotherapy, radiotherapy, and immunotherapy also cause the damage of chemo-surveillance to gravely enhance the development of fatal pulmonary fibrosis. Cancer patients, therefore, should be advised to avoid being infected by COVID-19, and if infected by COVID-19, targeted cancer therapy should become the priority choice to avoid the development of fatal symptom of pulmonary fibrosis.
Multiplication of the COVID-19 virus is of course the primary concern of viral infection. Vaccines, immuno-surveillance, and antiviral medicines such as interferon and nucleoside analogs can help to control COVID-19 infection and multiplication. But if the fatal symptom of pulmonary fibrosis has developed, there is no medicine available to treat this fatal symptom. The development of CDA formulations that can put out pulmonary fibrosis and Cancer Stem Cells (CSCs) is very urgent to save gravely ill patients of COVID-19 and cancer.
Keywords: Cancer, COVID-19, CDA formulations, chemo-surveillance, pulmonary fibrosis, wound healing
How to Cite
Downloads
References
Yahoo. COVID-19 pandemic. Yahoo Search; 2022.Wynn TA. Cellular and molecular mechanism of fibrosis. J Pathol. 2008;214 (2):199-210.
Rybinski B, Cukieman E. The wound healing, chronic fibrosis and cancer progressing triad. Physiol Genomics. 2014; 46(7):223-244.
Liau MC, Baker LL. Wound healing, evolution of cancer and war on cancer. Intl Res J Oncol. 2021;4(3):13-20.
Liau MC, Baker LL. Cancer arises as a consequence of wound not healing properly. Thus, perfection of wound healing must be the most appropriate strategy to win the war on cancer. Adv Complement Alt Med. 2021;6(3):584-586.
Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1989;13 (5):72-82.
Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022;6(3).
Print ISBN: 978-93-5547-607-4
Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction strategy is a better choice for cancer therapy. J Pharmacol Pharmaceu Pharmacovigi. 2020;4:029.
DOI:10.24966/PPP-5649/100029
Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.
Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol. 2022;6(3):8-20.
Liau MC, Chang CF, Saunder GF, Tsai YH. S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981;208(1):261-272.
Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Chin Oncol Cancer Res. 2010;7(2):86-96.
Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemotherapy. 1989;2(2): 187-199.
Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers for the differentiation therapy of cancer. J Cancer Tumor Intl. 2020;10(2):29-47.
Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res. 2021;4(1):7-10.
Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11(3): 166-168.
Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stud Ther J. 2019;4(1):1-15.
Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting of methylation enzymes. J Pharmacol Pharmaceu Pharmacovigi. 2019;3(1):009.
DOI:10.24966/PPP-5649/100009
Liau MC, Craig CL. On the mechanism of wound healing, and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 2021;5(3):25-31.
Itkin T, Rafii S. Leukemia cells “gas up” leaky bone marrow blood vessels. Cancer Cell. 2017;32(3):276-278.
Passaro D, Di Trullo A, Abarrategi A, Rouault-Pierre K, Foster K, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017;32 (3):324-341.
Virchow R. Die cellular pathilogie in ihrer begrundung auf physiologische und pathologische gewebelehve. Hirschwald. 1858;16:440.
Dvorak HF. Tumors: Wound that do not heal. N Engl J Med. 1986;315(26): 1650-1659.
MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020;13:648.
Liau MC, Kim JH, Fruehauf JP. Destabilizaion of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells. Online J Complement Alt Med. 2019;2(5): OJCAM.MS.ID.000546.
DOI:10.33542/OJCAM.2019.02.000546
Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent. 2007;7232578:82.
Feng F, Li Q, Ling CQ, Zhang Y Qin F, Wang H, et al. Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma. Chin J Clin Oncol. 2005;2(4): 706-716.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing. 2020;978-620-2-66889-7.
Liau MC, Fruehauf JP. It has been half a century since President declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. Adv Complement Alt Med. 2020;6(3):538-539.
Liau MC, Baker LL. Eradication of cancer stem cells to win the war on cancer. Nov Res Sci. 2021;6(5):1-3.
Liau MC, Baker LL. Cell differentiation agent formulations to win the war on cancer. Cancer Sci Res. 2022;5(2):1-4.